Careers in Israel
Careers in USA
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Mount Sinai Hospital
Annual and Quarterly Reports
Therapeutic product discovery
In the information age
The next wave in immuno-oncology
Jun 15, 2018
Compugen Announces $21 million Registered Direct Offering of Ordinary Shares and Warrants
Jun 11, 2018
Compugen Announces the Appointment of New Board Members
Our optimized process for predictive discovery of novel drug targets
Discovery & development of first-in-class monoclonal antibody therapeutics
Compugen, FROM CODE TO CURE
CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...
CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...
CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
May 09, 2018
Compugen First Quarter 2018 Earnings Conference Call
Apr 02, 2018
MedImmune License Agreement
Mar 13, 2018
Compugen Presentation at the Cowen and Company 38th Annual Health Care Conference
In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...
In March 2018, Compugen entered into an exclusive license agreement with MedImmune, the global biologics research and ...
Click here for more info about partnering with Compugen